ArticleCureus2025
Paraneoplastic Immune Thrombocytopenia in Estrogen Receptor (ER)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer: Clinical Implications and Therapeutic Strategies.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes the clinical course, diagnosis, and management of a premenopausal woman with a history of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC) who developed severe thrombocytopenia. After six years of the diagnosis of EBC (treated with curative intent), she presented with back pain, significant bruising, and menorrhagia. During the work-up, laboratory tests revealed severe thrombocytopenia, and imaging studies, including computed tomography scan and bone scintigraphy, demonstrated extensive bone lesions and adenopathies. A multidisciplinary approach was crucial in addressing her complex condition, considering potential diagnoses such as immune thrombocytopenia secondary to paraneoplastic syndrome versus hematologic malignancies. Given her history and clinical presentation, the most likely diagnosis was a recurrence of breast cancer with extensive bone metastasis. Despite challenges, including limited biopsy options due to thrombocytopenia, targeted anti-HER2 therapy and endocrine therapy (ET) led to significant clinical improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.